Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afrezza vs RAA in Pediatric Diabetes (INHALE-1)
NCT04974528Phase 3Completed
- Sponsor
- MannKind
- Start
- Sep 2021
- Primary completion
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of TI-Inhalation Powder B in type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by MannKind. Primary endpoint: Change in HbA1c at 26 weeks. Started Sep 2021; status: completed.
02
Drugs
TI-Inhalation Powder B
03
Conditions
type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04974528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04974528.